In a draft scoping document, the Institute for Clinical and Economic Review (ICER) outlined plans to review the comparative clinical effectiveness and value of treatments for lupus nephritis.
To ensure all perspectives are sufficiently considered, interested stakeholders are encouraged to submit feedback to the scope by email to email@example.com. All comments must meet ICER’s formatting specifications and be received by 5 PM ET on September 21, 2020. Additional guidance is provided in ICER’s Patient Participation Guide and Manufacturer Engagement Guide.
ICER also welcomes submissions detailing examples of low-value care practices within these clinical areas that provide strategies to reduce waste and preserve resources for high-value, potentially higher-cost treatments. A revised scoping document for each review will be posted after the public comment period on or about September 29, 2020. For more information about ICER, please visit ICER’s website.